Kiadis Pharma announces a glob­al col­lab­o­ra­tion with the Thalassaemia International Federation

~ ATIR201™ on track to enter Phase I/II clin­i­cal devel­op­ment in Q1 2016 ~

Amsterdam, The Netherlands, December 21, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces a col­lab­o­ra­tion with the Thalassaemia International Federation (TIF), an inter­na­tion­al­ly renowned organ­i­sa­tion that seeks to address the needs of patients, car­ers, health­care pro­fes­sion­als and the gen­er­al pub­lic in the area of tha­las­saemia, an inher­it­ed blood dis­or­der which results in improp­er oxy­gen trans­port and destruc­tion of red blood cells in a patient.
With sup­port of inter­na­tion­al tha­las­saemia experts, through the exten­sive net­work of the TIF, Kiadis Pharma aims to devel­op inno­v­a­tive prod­ucts to improve treat­ment of tha­las­saemia patients and will be enter­ing clin­i­cal devel­op­ment in the first quar­ter of 2016. Kiadis Pharma believes that its prod­uct ATIR201™ has the poten­tial to address the cur­rent risks and lim­i­ta­tions con­nect­ed with hematopoi­et­ic stem cell trans­plan­ta­tion (HSCT), being graft-ver­sus-host dis­ease (GVHD), oppor­tunis­tic infec­tions and lim­it­ed donor avail­abil­i­ty, and make HSCT a first-choice treat­ment of β-tha­las­saemia major.
The col­lab­o­ra­tion will allow the TIF to fur­ther expand its inter­na­tion­al edu­ca­tion­al and aware­ness pro­grams for patients and health-care pro­fes­sion­als, with a spe­cif­ic focus on hematopoi­et­ic stem cell trans­plan­ta­tion (HSCT) as a cura­tive treat­ment for tha­las­saemia patients.

Manfred Rüdiger, PhD, Chief Executive Officer of Kiadis Pharma, com­ment­ed: “Given our com­mit­ment to tha­las­saemia, we are pleased to be work­ing close­ly with the Thalassaemia International Federation. The col­lab­o­ra­tion will give Kiadis Pharma the oppor­tu­ni­ty to obtain valu­able sci­en­tif­ic feed­back, advice and sup­port in fur­ther devel­op­ing inno­v­a­tive treat­ments for tha­las­saemia patients.

Androulla Eleftheriou, Executive Director of Thalassaemia International Federation (TIF), added: “We look for­ward to work­ing more close­ly with Kiadis Pharma. The col­lab­o­ra­tion will allow us to fur­ther expand on our ongo­ing edu­ca­tion­al and aware­ness pro­grams sup­port­ing patients, car­ers and health care pro­fes­sion­als in their efforts to suc­cess­ful­ly treat tha­las­saemia. The pos­si­bil­i­ty of reduc­ing the risks of HSCT will allow the cure of a greater num­ber of patients, sat­is­fy­ing the very exis­tence of TIF.

About Thalassaemia International Federation
The Thalassaemia International Federation (TIF) is a non-prof­it, non-gov­ern­men­tal umbrel­la organ­i­sa­tion found­ed in 1986 by a small group of patients and par­ents rep­re­sent­ing main­ly National Thalassaemia Associations in Cyprus, Greece, UK, USA and Italy – coun­tries where tha­las­saemia was first recog­nised as an impor­tant pub­lic health issue and where the first pro­grammes for its con­trol, includ­ing pre­ven­tion and clin­i­cal man­age­ment, began to be pro­mot­ed and imple­ment­ed. TIF’s mem­ber­ship today includes 190 mem­bers from 61 coun­tries. TIF works in offi­cial rela­tions with the World Health organ­i­sa­tion (WHO) since 1996 and with a num­ber of oth­er offi­cial health bod­ies and patient ori­ent­ed organ­i­sa­tions. TIF’s mis­sion is to pro­mote opti­mal qual­i­ty care for all patients with tha­las­saemia world­wide. More infor­ma­tion is avail­able at

Leave a Reply

Your email address will not be published. Required fields are marked *